Evidence map›Paper›PMID 40825131›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2025

Germline variants in

Eguzkine Ochoa, Ilona Zvetkova, Sunwoo Liv Lee, Nozomi Takahashi, Benoit Lan-Leung, Emma Hobson, Mahmoud Issa, Bryndis Yngvadottir, France Docquier, Fay Rodger and 9 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Germline variants inProceedings of the National Academy of Sciences of the United States of America · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Eguzkine Ochoa *Department of Genomic Medicine, University of Cambridge and National Institute for Health and Care Research Cambridge Biomedical Research Centre, Cambridge CB2 0QQ, United Kingdom.
Ilona Zvetkova *Wellcome-Medical Research Council Institute of Metabolic Science and Medical Research Council Metabolic Diseases Unit, University of Cambridge, Cambridge CB2 0QQ, United Kingdom.
Sunwoo Liv LeeDepartment of Genomic Medicine, University of Cambridge and National Institute for Health and Care Research Cambridge Biomedical Research Centre, Cambridge CB2 0QQ, United Kingdom.
Nozomi TakahashiDepartment of Genetics, University of Cambridge, Cambridge CB2 3EH, United Kingdom.
Benoit Lan-LeungDepartment of Genomic Medicine, University of Cambridge and National Institute for Health and Care Research Cambridge Biomedical Research Centre, Cambridge CB2 0QQ, United Kingdom.ORCID 0000-0002-2201-7917
Emma HobsonLeeds Clinical Genomics Service, Chapel Allerton Hospital, Leeds Teaching Hospitals National Health Service Trust, Leeds LS7 4SA, United Kingdom.
Mahmoud IssaLeeds Clinical Genomics Service, Chapel Allerton Hospital, Leeds Teaching Hospitals National Health Service Trust, Leeds LS7 4SA, United Kingdom.ORCID 0000-0002-3899-2821
Bryndis YngvadottirDepartment of Genomic Medicine, University of Cambridge and National Institute for Health and Care Research Cambridge Biomedical Research Centre, Cambridge CB2 0QQ, United Kingdom.
France DocquierDepartment of Genomic Medicine, University of Cambridge and National Institute for Health and Care Research Cambridge Biomedical Research Centre, Cambridge CB2 0QQ, United Kingdom.
Fay RodgerDepartment of Genomic Medicine, University of Cambridge and National Institute for Health and Care Research Cambridge Biomedical Research Centre, Cambridge CB2 0QQ, United Kingdom.
Dounia Foster-HallDepartment of Obstetrics and Gynaecology and National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge CB2 0SW, United Kingdom.
Graeme ClarkDepartment of Genomic Medicine, University of Cambridge and National Institute for Health and Care Research Cambridge Biomedical Research Centre, Cambridge CB2 0QQ, United Kingdom.
Ana ToribioDepartment of Genomic Medicine, University of Cambridge and National Institute for Health and Care Research Cambridge Biomedical Research Centre, Cambridge CB2 0QQ, United Kingdom.
Ezequiel MartinDepartment of Genomic Medicine, University of Cambridge and National Institute for Health and Care Research Cambridge Biomedical Research Centre, Cambridge CB2 0QQ, United Kingdom.
Leonardo BottoloDepartment of Genomic Medicine, University of Cambridge and National Institute for Health and Care Research Cambridge Biomedical Research Centre, Cambridge CB2 0QQ, United Kingdom.ORCID 0000-0002-6381-2327
Anne C Ferguson-SmithDepartment of Genetics, University of Cambridge, Cambridge CB2 3EH, United Kingdom.
Wolfgang FischleBioscience Program, Biological and Environmental Science and Engineering Division, King Abdullah University of Science and Technology, Thuwal 23955, Kingdom of Saudi Arabia.ORCID 0000-0002-2335-8932
Miguel Constancia *Wellcome-Medical Research Council Institute of Metabolic Science and Medical Research Council Metabolic Diseases Unit, University of Cambridge, Cambridge CB2 0QQ, United Kingdom.
Eamonn R Maher *Department of Genomic Medicine, University of Cambridge and National Institute for Health and Care Research Cambridge Biomedical Research Centre, Cambridge CB2 0QQ, United Kingdom.ORCID 0000-0002-6226-6918

Funding

Alan Turing Institute under the Engineering and Physical Sciences Research Council EP/N510129/1EpiGenRare MRC Rare Diseases Node funding MR/Y008170/1King Abdullah University of Science and Technology (KAUST) OSR-GRG2019-4043Marie Curie Initial Training Network Award INGENIUMMedical Research Counc MRC_MC_UU_12012/4NIHR | NIHR Cambridge Biomedical Research Centre (NIHR Cambridge BRC) BRC-1215-20014Rosetrees Trust (Rosetrees) PhDPlus
6 · The paper itself

Abstract

The investigation of congenital imprinting disorders (CIDs) provides opportunities to elucidate the molecular mechanisms and role of genomic imprinting in development and human disease. Beckwith-Wiedemann spectrum (BWSp) is a prototypic CID resulting from genetic and epigenetic alterations of imprinted genes at chromosome 11p15.5. In up to a quarter of individuals with BWSp, the epigenetic alterations are not confined to 11p15.5 imprinting control regions but also involve other imprinted gene clusters (multilocus imprinting disturbance; MLID). In a consanguineous family with two children diagnosed with BWSp and MLID, the affected individuals were homozygous for a missense variant in

Indexed as

Beckwith-Wiedemann SyndromeDNA MethylationEpigenesis, GeneticGenomic ImprintingUbiquitin-Protein LigasesAllelesCCAAT-Enhancer-Binding ProteinsConsanguinityFemaleHumansInfantMaleMultigene FamilyMutation, MissensePhenotypeCCAAT-Enhancer-Binding ProteinsUbiquitin-Protein LigasesUHRF1 protein, humanUhrf1 protein, mousecongenital imprinting disordergenomic imprintinginheritedmethylationmultilocus imprinting disturbance

Identifiers

PMID40825131
PMCPMC12403135

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.